Caspase Inhibition with XIAP as an Adjunct to AAV Vector Gene-Replacement Therapy: Improving Efficacy and Prolonging the Treatment Window
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
PURPOSE: AAV-mediated gene therapy in the rd10 mouse, with retinal degeneration caused by mutation in the rod cyclic guanosine monophosphate phosphodiesterase β-subunit (PDEβ) gene, produces significant, but transient, rescue of photoreceptor structure and function. This study evaluates the ability of AAV-mediated delivery of X-linked inhibitor of apoptosis (XIAP) to enhance and prolong the efficacy of PDEβ gene-replacement therapy. METHODS: Rd10 mice were bred and housed in darkness. Two groups of animals were generated: Group 1 received sub-retinal AAV5-XIAP or AAV5-GFP at postnatal age (P) 4 or 21 days; Group 2 received sub-retinal AAV5-XIAP plus AAV5- PDEβ, AAV5-GFP plus AAV5- PDEβ, or AAV- PDEβ alone at age P4 or P21. Animals were maintained for an additional 4 weeks in darkness before being moved to a cyclic-light environment. A subset of animals from Group 1 received a second sub-retinal injection of AAV8-733-PDEβ two weeks after being moved to the light. Histology, immunohistochemistry, Western blots, and electroretinograms were performed at different times after moving to the light. RESULTS: Injection of AAV5-XIAP alone at P4 and 21 resulted in significant slowing of light-induced retinal degeneration, as measured by outer nuclear thickness and cell counts, but did not result in improved outer segment structure and rhodopsin localization. In contrast, co-injection of AAV5-XIAP and AAV5-PDEβ resulted in increased levels of rescue and decreased rates of retinal degeneration compared to treatment with AAV5-PDEβ alone. Mice treated with AAV5-XIAP at P4, but not P21, remained responsive to subsequent rescue by AAV8-733-PDEβ when injected two weeks after moving to a light-cycling environment. CONCLUSIONS: Adjunctive treatment with the anti-apoptotic gene XIAP confers additive protective effect to gene-replacement therapy with AAV5-PDEβ in the rd10 mouse. In addition, AAV5-XIAP, when given early, can increase the age at which gene-replacement therapy remains effective, thus effectively prolonging the window of opportunity for therapeutic intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Retinal degeneration mutants in the mouse
Chang, B., Hawes, N. L., Hurd, R. E., Davisson, M. T., Nusinowitz, S., & Heckenlively, J. R. (2002) · Vision Research · doi:10.1016/s0042-6989(01)00146-8 · Cited by 840 · cited 2×
“The retinal degeneration 10 (rd10) mouse is a model of autosomal-recessive RP caused by a point mutation of the Pde6b gene[19].”
BackgroundThe X-linked inhibitor of apoptosis (XIAP) prevents cell death in axotomized CNS neurons in vivo
Kügler, S., Straten, G., Kreppel, F., Isenmann, S., Liston, P., & Bähr, M. (2000) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400712 · Cited by 84 · cited 1×
“Previous studies have shown that adeno-associated viral (AAV) constructs encoding XIAP exert protective effects in various models of retinal injury and disease including retinal ischemia [10], ganglion cell death induced by axotomy [11,12] or increased intraocular pressure [13], chemotoxic insult [14,15], retinal deta…”
Background
Cited by
Immunology of AAV-Mediated Gene Transfer in the Eye
Willett, K., & Bennett, J. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00261 · Cited by 105
“Additional studies in cell and animal models have identified alternative neuroprotective agents, such as erythropoietin (EPO) (52), rod-derived ciliary neurotrophic factor (RdCVF) (53), and X-linked inhibitor of apoptosis (XIAP) (54).”
BackgroundGene therapy for retinal disease
McClements, M. E., & MacLaren, R. E. (2013) · Translational Research · doi:10.1016/j.trsl.2012.12.007 · Cited by 80
Gene therapy for inherited retinal disease: Long-term durability of effect
Leroy, B. P., Fischer, M. D., Flannery, J. G., MacLaren, R. E., Dalkara, D., Scholl, H. P. N., Chung, D. C., Spera, C., Viriato, D., & Banhazi, J. (2023) · Ophthalmic Research · doi:10.1159/000526317 · Cited by 70
Petit, L., Ma, S., Cheng, S.-Y., Gao, G., & Punzo, C. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.020 · Cited by 24
“As well, another study reported that subretinal injection of AAV2/5-smCBAmPde6b vector (1 · 10(10) genome copies) in rd10 mice at PND4 (before the onset of PR dystrophy) or PND21 (after the onset of PR dystrophy) resulted in similar (partial) therapeutic effects.(67) Second, the results indicate that if PR integrity d…”
Metadata
- Authors
- Yao, J., Jia, L., Khan, N., Zheng, Q.-D., Moncrief, A., Hauswirth, W. W., Thompson, D. A., & Zacks, D. N.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-05-16
- Volume
- 7
- Issue
- 5
- Pages
- e37197
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1969191647
- Cited by
- 21
- References
- 2
- FWCI
- 1.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.